Drug profile · INN
polidocanol
ASCLERA
polidocanol (ASCLERA) is a unknown. Route of administration: intravenous. Current US regulatory status: approved.
FDA: approved
US status approved
Patents linked 0
Pipeline programs 45
News articles 0
Drug details — polidocanol
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 45
- Data quality
- 0.84
Quick answer
polidocanol (ASCLERA) is a unknown. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
INN polidocanol
Brand ASCLERA
Mechanism Unknown
Route INTRAVENOUS
Formulation SOLUTION
Mechanism of action
Unknown
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is polidocanol?
polidocanol (ASCLERA) is a unknown. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for polidocanol?
ASCLERA is a marketed brand name for polidocanol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of polidocanol?
polidocanol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.